Buloyan Sona, Harutyunyan Arpine, Gasparyan Hrachik, Sakeyan Anahit, Shahkhatuni Astghik, Zakirova Natalia F, Yusubalieva Gaukhar, Kirillov Ilya M, Fedyakina Irina T, Solyev Pavel N, Lipatova Anastasia V, Bogomolov Mikhail A, Prassolov Vladimir S, Lebedev Timofey D, Ivanov Alexander V
Scientific Technological Center of Organic and Pharmaceutical Chemistry, National Academy of Sciences of the Republic of Armenia, 0019 Yerevan, Armenia.
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.
Int J Mol Sci. 2025 Apr 23;26(9):3991. doi: 10.3390/ijms26093991.
Advances in medicinal chemistry have led to the development of anticancer and anti-infectious drugs. However, many types of cancer and viral infections such as hepatitis B virus or SARS-CoV-2 are still treated ineffectively. Therefore, further development of effective and selective lead compounds as potential drugs is still highly demanded. In this study, we synthesized a novel series of piperazine-substituted pyranopyridines and evaluated their anticancer and antiviral properties. Antiproliferative activity was determined in a panel of various tumor cell lines as well as non-tumor hepatic HepaRG cells. Mechanisms of cytotoxicity were assessed by fluorescent microscopy techniques. Antiviral activity was analyzed towards DNA and RNA viruses in infectious cell culture systems. Several compounds showed antiproliferative activity towards various cancer cell lines at micromolar and submicromolar concentrations. Mechanisms of cytotoxicity involve the induction of apoptosis and are not mediated via ERK1/2 pathway or oxidative stress. Several compounds exhibit selective activity against hepatitis B virus by preventing the formation of virion particles. This study led to the identification of a novel class of piperazine-substituted pyranopyridines with antiproliferative activity towards a wide range of tumor cell lines as well as the non-toxic inhibitor of HBV virion production.
药物化学的进展已促使抗癌和抗感染药物的开发。然而,许多类型的癌症以及诸如乙型肝炎病毒或严重急性呼吸综合征冠状病毒2(SARS-CoV-2)等病毒感染仍然无法得到有效治疗。因此,仍然迫切需要进一步开发作为潜在药物的有效且具有选择性的先导化合物。在本研究中,我们合成了一系列新型的哌嗪取代的吡喃并吡啶,并评估了它们的抗癌和抗病毒特性。在一组各种肿瘤细胞系以及非肿瘤性肝HepaRG细胞中测定了抗增殖活性。通过荧光显微镜技术评估细胞毒性机制。在感染性细胞培养系统中分析了对DNA和RNA病毒的抗病毒活性。几种化合物在微摩尔和亚微摩尔浓度下对各种癌细胞系显示出抗增殖活性。细胞毒性机制涉及细胞凋亡的诱导,且不是通过细胞外信号调节激酶1/2(ERK1/2)途径或氧化应激介导的。几种化合物通过阻止病毒粒子的形成对乙型肝炎病毒表现出选择性活性。本研究导致鉴定出一类新型的哌嗪取代的吡喃并吡啶,其对多种肿瘤细胞系具有抗增殖活性,并且是乙型肝炎病毒病毒粒子产生的无毒抑制剂。